ST. LOUIS – A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement.
U.S. District Judge Rodney Sippel of St. Louis approved the settlement in February, and it was finalized Thursday.
The lead attorney for the claimants said the deal is final. Merck confirmed that the agreement is final.
Denton said about 3,800 claimants will share in the settlement.
NuvaRing is a hormonal contraceptive inside a flexible ring that slowly releases two hormones into the vaginal wall. Merck has been selling NuvaRing since 2002.
The lawsuits allege faulty design and testing, and claim the potential hazards of the device were not adequately disclosed.
Severe side effects connected to NuvaRing include blood clots, strokes and heart attacks, high blood pressure and heart disease, and cancer of the reproductive organs and breast.